{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:42:21Z","timestamp":1781628141065,"version":"3.54.5"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:00:00Z","timestamp":1539043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0205018","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T13:49:53Z","timestamp":1539092993000},"page":"e0205018","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents"],"prefix":"10.1371","volume":"13","author":[{"given":"Raffaella","family":"Cincinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loana","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Artali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario B.","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"La Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Melito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Colelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cardile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Signorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Frusciante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8813-8922","authenticated-orcid":true,"given":"Sabrina","family":"Dallavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,10,9]]},"reference":[{"key":"ref1","first-page":"1123","article-title":"Clin. Combining Molecularly Targeted Agents: Is More Always Better?","volume":"23","author":"R Sundar","year":"2017","journal-title":"Cancer Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bcp.2015.06.006","article-title":"Perspectives in the development of hybrid bifunctional antitumour agents","volume":"96","author":"L Musso","year":"2015","journal-title":"Biochem. Pharmacol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ejmech.2017.11.021","article-title":"Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors","volume":"143","author":"R Cincinelli","year":"2018","journal-title":"Eur. J. Med. Chem"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/17460441.2016.1135125","article-title":"An overview of molecular hybrids in drug discovery","volume":"11","author":"G B\u00e9rub\u00e9","year":"2016","journal-title":"Expert Opin. Drug Discov"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"28313","DOI":"10.1039\/C6RA24662A","article-title":"Small hybrid heteroaromatics: resourceful biological tools in cancer research","volume":"7","author":"V Abbot","year":"2017","journal-title":"RSC Advances"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"J Roche","year":"2016","journal-title":"Eur. J. Med. Chem"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12272-015-0571-1","article-title":"Histone deacetylase inhibitors in hematological malignancies and solid tumors","volume":"38","author":"P Chun","year":"2015","journal-title":"Arch. Pharm. Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cb300648v","article-title":"Drugging Topoisomerases: Lessons and Challenges","volume":"8","author":"Y Pommier","year":"2013","journal-title":"ACS Chem Biol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11101-015-9397-1","article-title":"Current status of CPT and its analogues in the treatment of malignancies","volume":"14","author":"G Hu","year":"2015","journal-title":"Phytochem. Rev"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.dnarep.2017.06.005","article-title":"The Top1 paradox: Friend and foe of the eukaryotic genome","volume":"56","author":"N Kim","year":"2017","journal-title":"DNA Repair"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/med.21342","article-title":"Perspectives on Biologically Active Camptothecin Derivatives","volume":"35","author":"Y.-Q Liu","year":"2015","journal-title":"Med. Res. Rev"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bmcl.2016.12.085","article-title":"The long story of camptothecin: From traditional medicine to drugs","volume":"27","author":"E Martino","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10637-013-0044-7","article-title":"A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors","volume":"32","author":"S Ghamande","year":"2014","journal-title":"Invest New Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1007\/s10637-011-9679-4","article-title":"The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56\u20133722 (formerly BAY 38\u20133441), in patients with recurrent or metastatic colorectal cancer resistant\/refractory to irinotecan","volume":"30","author":"M Slingerland","year":"2012","journal-title":"Invest New Drugs"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2016.12.023","article-title":"Safe approaches for camptothecin delivery: Structural analogues and nanomedicines","volume":"247","author":"P Botella","year":"2017","journal-title":"J. Control. Release"},{"key":"ref16","first-page":"1218","article-title":"Novel Polyamine\u2013Naphthalene Diimide Conjugates Targeting Histone Deacetylases and DNA for Cancer Phenotype Reprogramming. ACS Med","volume":"8","author":"A Pasini","year":"2017","journal-title":"Chem. Lett"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/1535-7163.MCT-09-0254","article-title":"Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis","volume":"8","author":"F Bruzzese","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11060-010-0127-7","article-title":"Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines","volume":"99","author":"B Sarcar","year":"2010","journal-title":"J Neurooncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3727\/096504011X12970940207841","article-title":"Antitumor Effect of Suberoylanilide Hydroxamic Acid and Topotecan in Renal Cancer Cells","volume":"19","author":"A Sato","year":"2011","journal-title":"Oncol Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1517\/13543784.2011.617740","article-title":"Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma","volume":"20","author":"PN Munster","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref21","first-page":"1509","article-title":"Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts","volume":"24","author":"YS Na","year":"2010","journal-title":"Oncol Rep"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.biopha.2016.10.057","article-title":"Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells","volume":"84","author":"L Wasim","year":"2016","journal-title":"Biomed. Pharmacother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e0142704","DOI":"10.1371\/journal.pone.0142704","article-title":"Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3\/AKT\/MAPK Pathways","volume":"10","author":"VB Sampson","year":"2015","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4161\/cbt.19848","article-title":"Combination of HDAC and topoisomerase inhibitors in small cell lung cancer","volume":"13","author":"J Gray","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1021\/jm0108092","article-title":"Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity","volume":"44","author":"S Dallavalle","year":"2001","journal-title":"J. Med. Chem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejmech.2013.02.022","article-title":"Design, modeling, synthesis and biological activity evaluation of camptothecin-linked platinum anticancer agents","volume":"63","author":"R Cincinelli","year":"2013","journal-title":"Eur. J. Med. Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1021\/jm000944z","article-title":"Novel 7-Substituted Camptothecins with Potent Antitumor Activity","volume":"43","author":"S Dallavalle","year":"2000","journal-title":"J Med. Chem"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s008940100045","article-title":"GROMACS 3.0: a package for molecular simulation and trajectory analysis","volume":"7","author":"E Lindahj","year":"2001","journal-title":"Mol. Model. Annu"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/jcc.10349","article-title":"A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations","volume":"24","author":"Y Duan","year":"2003","journal-title":"J. Comp. Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F","article-title":"How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?","volume":"21","author":"J Wang","year":"2000","journal-title":"J. Comp. Chem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/jcc.20634","article-title":"A semiempirical free energy force field with charge-based desolvation","volume":"28","author":"R Huey","year":"2007","journal-title":"J. Comput. Chem"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1287\/moor.6.1.19","article-title":"Minimization by Random Search Techniques","volume":"6","author":"FJ Solis","year":"1981","journal-title":"Math. Oper. Res"},{"key":"ref33","first-page":"57","article-title":"Python: a programming language for software integration and development","volume":"17","author":"MF Sanner","year":"1999","journal-title":"J. Mol. Graph. Model"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/0040-4020(80)80168-2","article-title":"Iterative partial equalization of orbital electronegativity\u2014a rapid access to atomic charges","volume":"36","author":"J Gasteiger","year":"2008","journal-title":"Tetrahedron"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.bcp.2006.11.004","article-title":"Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series","volume":"73","author":"M De Cesare","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1021\/jm060285b","article-title":"Synthesis and Cytotoxic Activity of Polyamine Analogues of Camptothecin","volume":"49","author":"S Dallavalle","year":"2006","journal-title":"J. Med. Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1021\/jm070178x","article-title":"Functional Differences in Epigenetic ModulatorsSuperiority of Mercaptoacetamide-Based Histone Deacetylase Inhibitors Relative to Hydroxamates in Cortical Neuron Neuroprotection Studies","volume":"50","author":"AP Kozikowski","year":"2007","journal-title":"J. Med. Chem"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bmcl.2005.01.006","article-title":"Chemistry and biology of mercaptoacetamidesas novel histone deacetylase inhibitors","volume":"15","author":"B Chen","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1016\/j.bmcl.2013.03.108","article-title":"Dual-acting histone deacetylase-topoisomerase I inhibitors","volume":"23","author":"G Guerrant","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"ref40","unstructured":"Chen Y, Chen Y. Preparation of HDAC inhibiting derivatives of camptothecin. WO2012096832 (2012)."},{"key":"ref41","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1038\/s41598-017-03417-1","article-title":"Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach","volume":"7","author":"KC Hsu","year":"2017","journal-title":"Scientific Reports"},{"key":"ref42","first-page":"661","article-title":"Cell Death Dis","volume":"9","author":"J Zou","year":"2018","journal-title":"Cell Death Dis"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/15384101.2014.1000134","article-title":"Senescence from G2 arrest, revisited","volume":"14","author":"V Gire","year":"2015","journal-title":"Cell Cycle"},{"key":"ref44","first-page":"63","article-title":"Modern management of malignant pleural mesothelioma","volume":"7","author":"SC Patel","year":"2016","journal-title":"Lung Cancer: Targets and Therapy"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"TA Yap","year":"2017","journal-title":"Nature Reviews Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0205018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T11:12:40Z","timestamp":1540293160000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0205018"}},"subtitle":[],"editor":[{"given":"Fenfei","family":"Leng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,9]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0205018","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,9]]}}}